Login
Login     |     Register     |     Recover Username/Password

Boris Peaker

Oppenheimer & Co. Inc.

Boris Peaker is an Executive Director and Senior Analyst at Oppenheimer & Co. Inc., covering the emerging biotechnology sector. Prior to joining Oppenheimer & Co., Inc., Mr. Peaker worked at Rodman & Renshaw covering small and midcap biotech companies across multiple therapeutic areas. Prior to Rodman & Renshaw, Mr. Peaker covered mid- and large-cap U.S.-based biopharmaceutical and biotechnology companies at Cowen Group, Inc., on their biotechnology team. Mr. Peaker began his career as a Consultant at Keelin Reeds Partners in California, working exclusively with biotech and pharmaceutical companies on, among other things, asset valuation, R&D portfolio management, M&A strategy, and royalty and equity financing. Mr. Peaker holds a Ph.D. in biophysics from Stanford University and a dual B.S. in physics and chemistry from SUNY at Stony Brook.

Finding Innovation in Biotechnology for Cell Therapy, Oncology and Orphan Drugs
April 26, 2013 - Pharmaceuticals

Emerging-Growth Opportunities in Oncology Biotech
September 17, 2012 - Pharmaceuticals

TSWT - Subscribe now!

The Wall Street Transcript is a completely unique resource for investors and business researchers.

Over 20,000 CEO, Equity Analyst and Money Manager Interviews

TWST Newsletter

Weekly email with New In-Depth Interviews

Most Popular Interviews
Opportunities in Hepatitis C and Genomic Technologies
David Ferreiro

Published April 26, 2014 in Biotechnology and Pharmaceuticals

Buy ($75)
Investing in Health Care Innovation
Finny Kuruvilla

"We’re a faith-based and socially responsible investing firm"

Published May 16, 2013 in Investing in Health Care

Buy ($75)
A Health Sciences Fund with a Long-Term Focus
Mark W. Oelschlager

"The fund is about $40 million in assets"

Published May 16, 2013 in Investing in Health Care

Buy ($75)
High-Yield Canadian Power Companies
John McIlveen

Published May 14, 2013 in High-Yield Equity Securities

Buy ($75)
Most Popular Reports
Investing in Health Care

Published May 16, 2013

Topics Covered: Health Care - Electronic Health Record Adoption - Biotechnology and Pharmaceutical Investing - Biotechnology and Pharmaceuticals - Biotechnology and Pharmaceutical Companies Valuation - Platform Interoperability and Data Analytics - HITECH Act Incentives - Affordable Care Act
Buy ($175)
Internet Services

Published May 10, 2013

Topics Covered: Increased Mobile Content Traffic - Chinese Online Monetization Trends - Internet Infrastructure and Services Consolidation - Social Networking Economics -
Buy ($175)
Investing Strategies

Published May 10, 2013

Topics Covered: Investing in Financial Services - Long-Term Investing - Large Cap Investing - Value Investing - High Quality Companies - Bottom-up Investing - All-Cap Growth Investing - Investing in Emerging Markets
Buy ($175)
Top Company Interviews
TWST
Register for a Free Account to gain greater access to The Wall Street Transcript right now